IL1A and adrenocortical insufficiency: A significant signal for secondary adrenocortical insufficiency was found for the IL-1 inhibitor class (ROR: 7.09, 95% CI = 2.6–19.35) and specifically for canakinumab (ROR: 7.8, 95% CI = 2.46–24.7).